Mamtha Balla: Invasive Fusarium in immuno-compromised patients
Mamtha Balla, Transplant Oncology-ID fellow at
“I had an amazing experience speaking at the Citywide conference at the medical center in Houston MD Anderson Cancer Center about invasive Fusarium in immuno-compromised patients. There were over 300 invitees, and it was an incredible opportunity to share and learn about this important topic.
Fusarium infection has a 100% mortality rate if not treated early, especially in immunocompromised patients.
To reduce the risk of exposure for immunocompromised patients, every effort is made, including placing high-risk patients in areas with HEPA filters and positive pressure, as well as avoiding contact with potential sources of infection such as tap water and cleaning showers.
Skin lesions – particularly onychomycosis serve as portal entry for fusariosis, oncologist need to be aware.
Liposomal amphotericin B, voriconazole and posaaconazole or in combination is the corner stone of the treatment.
It’s important to remember that Fosmanogepix and Olorofim are still awaiting further studies and FDA approval hopeful.
Supporting these immuno-compromised patients is crucial for preventing mortality and morbidity. Let’s keep them in our thoughts and do all we can to help.”
Source: Mamtha Balla/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023